Freshly minted as a "unicorn," the Utah healthcare data analytics powerhouse is building up a new life sciences division to aid biotech development and precision medicine.
The UK-based maker of clinical genomics interpretation software is moving into the US and China after carefully researching the differences from European markets.
The Shenzhen-based company offers personal genomics services in China that are similar to those provided by 23andMe, Ancestry, and Helix in the US.
The change will be felt most immediately in Europe, where the Dutch molecular diagnostics company recently secured a CE-IVD mark for its MammaPrint BluePrint kit.
Centogene opened a Boston office in December and plans to open a lab there in a few months as it awaits an FDA decision on its clinical tool.
The Singapore-based firm has established a US subsidiary and named distributors to sell its products across Europe, the Middle East, and Asia.
LifeOmic, founded less than a year ago, expects omic data sets to become as clinically relevant as diagnostic medical imaging.
The La Jolla, California-based firm is moving beyond its US home market into other regions that promise growth for synthetic genomics providers.
The new division will enable BGI to expand partnerships with universities, companies, and health and agriculture-related organizations, among other things.
Pacific Biosciences announced this week that it has reached the final developmental milestone of its commercialization and licensing agreement with Roche.
In a cartoon, Vox explores the lack of women among this year's winners of the Nobel Prize.
Science reports a new US defense bill would establish two groups aimed at combating foreign influence on research.
Nature Biotechnology discusses promising early results from two clinical trials of CRISPR-based therapy for β-thalassemia and sickle cell disease.
In Cell this week: analysis of tissue clones, metagenomic studies of ocean water samples, and more.